Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Edler Peta, Rajasekhar Megha, Price David J, Adam Ishag, Awab Ghulam Rahim, Barber Bridget E, Brasil Larissa W, Chamma-Siqueira Nathália N, Chu Cindy S, Cui Liwang, Daher André, Gomes Margarete do Socorro M, Gonzalez-Ceron Lilia, Grigg Matthew J, Karunajeewa Harin, Lacerda Marcus V G, Ladeia-Andrade Simone, Leslie Toby, Ley Benedikt, Lidia Kartini, Llanos-Cuentas Alejandro, Longley Rhea J, Manning Laurens, Mekonnen Daniel Abebe, Monteiro Wuelton Marcelo, Moore Brioni R, Nosten Francois, Pasaribu Ayodhia Pitaloka, Pereira Dhelio B, Poespoprodjo Jeanne Rini, Pukrittayakamee Sasithon, Rijal Komal Raj, Saravu Kavitha, Siqueira André M, Sutanto Inge, Taylor Walter R J, Thanh Pham Vinh, Thriemer Kamala, Vieira José Luiz F, White Nicholas J, Yeshiwondim Asnakew K, Zuluaga-Idarraga Lina M, Guerin Philippe J, Simpson Julie A, Price Ric N, Commons Robert J, WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group
Аннотация
METHODS: A living systematic review identified efficacy studies of uncomplicated P. vivax malaria including patients treated with daily primaquine regimens, published since January 1, 2000. Available data were pooled and an R Shiny app was developed to integrate statistical analyses performed using R and Stata that assessed the impact of primaquine mg/kg dose on efficacy, hematological safety and gastrointestinal tolerability.
RESULTS: As of January 16, 2025, a total of 9,270 individual patient data records from 41 studies have been collated into the standardized repository. Open-access automated reports were generated for user-selected countries or regions to investigate location specific effects of primaquine dose on efficacy, safety and tolerability. The reports include visual and tabular displays of the outcomes.
CONCLUSIONS: These automated reports leverage a large database to provide accessible data for national and regional policy makers and researchers to assess the clinical consequences of different primaquine regimens in different endemic settings. The reports will inform local and regional policy decisions and research priorities in vivax-endemic areas.